{
  "source": "PA-Notification-Itovebi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1462-1\nProgram Prior Authorization/Notification\nMedication Itovebi™ (inavolisib)\nP&T Approval Date 12/2024\nEffective Date 3/1/2025\n1. Background:\nItovebi is a kinase inhibitor indicated in combination with palbociclib and fulvestrant for the\ntreatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive,\nhuman epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast\ncancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant\nendocrine therapy.\nCoverage Information:\nMembers will be required to meet the criteria below for coverage. For members under the age\nof 19 years, the prescription will automatically process without a coverage review.\nSome states mandate benefit coverage for off-label use of medications for some diagnoses or\nunder some circumstances. Some states also mandate usage of other Compendium references.\nWhere such mandates apply, they supersede language in the benefit document or in the\nnotification criteria.\n2. Coverage Criteriaa:\nA. Patients less than 19 years of age\n1. Itovebi will be approved based on the following criterion:\na. Patient is less than 19 years of age\nAuthorization will be issued for 12 months.\nB. Breast Cancer\n1. Initial Authorization\na. Itovebi will be approved based on all of the following criteria:\n(1) Diagnosis of breast cancer\n-AND-\n(2) Disease is one of the following:\n(a) Locally advanced\n(b) Metastatic\n© 2024 UnitedHealthcare Services Inc.\n1\n-AND-\n(3) Disease is hormone receptor (HR)-positive\n-AND-\n(4) Disease is human epidermal growth factor receptor 2 (HER2)-negative\n-AND-\n(5) Disease is PIK3CA-mutation positive\n-AND-\n(6) Used following recurrence on or after completing adjuvant endocrine therapy\n-AND-\n(7) Used in combination with both of the following:\n(a) Ibrance (palbociclib)\n(b) Fulvestrant\nAuthorization will be issued for 12 months.\n2. Reauthorizati",
    "r completing adjuvant endocrine therapy\n-AND-\n(7) Used in combination with both of the following:\n(a) Ibrance (palbociclib)\n(b) Fulvestrant\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Itovebi will be approved based on the following criterion:\n(1) Patient does not show evidence of progressive disease while on Itovebi therapy\nAuthorization will be issued for 12 months.\nC. NCCN Recommended Regimens\nThe drug has been recognized for treatment of the cancer indication by The National\nComprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category\nof Evidence and Consensus of 1, 2A, or 2B\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n© 2024 UnitedHealthcare Services Inc.\n2\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim\nlogic. Use of automated approval and re-approval processes varies by program and/or\ntherapeutic class.\n• Supply limit may be in place.\n4. References:\n1. Itovebi [package insert]. South San Francisco, CA: Genentech, Inc; October 2024.\nProgram Prior Authorization/Notification - Itovebi™ (inavolisib)\nChange Control\nDate Change\n12/2024 New program.\n© 2024 UnitedHealthcare Services Inc.\n3"
  ]
}